JP2014522414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522414A5 JP2014522414A5 JP2014514910A JP2014514910A JP2014522414A5 JP 2014522414 A5 JP2014522414 A5 JP 2014522414A5 JP 2014514910 A JP2014514910 A JP 2014514910A JP 2014514910 A JP2014514910 A JP 2014514910A JP 2014522414 A5 JP2014522414 A5 JP 2014522414A5
- Authority
- JP
- Japan
- Prior art keywords
- hemodialysis
- composition
- dialysis
- serum phosphorus
- period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001631 haemodialysis Methods 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 26
- 230000000322 hemodialysis Effects 0.000 claims description 24
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 16
- 239000011574 phosphorus Substances 0.000 claims description 16
- 229910052698 phosphorus Inorganic materials 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 13
- 238000000502 dialysis Methods 0.000 claims description 12
- 125000002091 cationic group Chemical group 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 5
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 4
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 4
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 4
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 4
- 239000002694 phosphate binding agent Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 229940121399 calcium-sensing receptor agonists Drugs 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 229960000478 cinacalcet hydrochloride Drugs 0.000 claims description 2
- QANQWUQOEJZMLL-PKLMIRHRSA-N cinacalcet hydrochloride Chemical group Cl.N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 QANQWUQOEJZMLL-PKLMIRHRSA-N 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 230000006371 metabolic abnormality Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 2
- 101710159793 Extracellular calcium-sensing receptor Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 230000002092 calcimimetic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494874P | 2011-06-08 | 2011-06-08 | |
| US61/494,874 | 2011-06-08 | ||
| PCT/US2012/041759 WO2012170955A1 (en) | 2011-06-08 | 2012-06-08 | Therapeutic agents for regulating serum phosphorus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522414A JP2014522414A (ja) | 2014-09-04 |
| JP2014522414A5 true JP2014522414A5 (enExample) | 2015-07-23 |
| JP5982473B2 JP5982473B2 (ja) | 2016-08-31 |
Family
ID=46321485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514910A Active JP5982473B2 (ja) | 2011-06-08 | 2012-06-08 | 血清リンを調節するための治療剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8969299B2 (enExample) |
| EP (1) | EP2717896B1 (enExample) |
| JP (1) | JP5982473B2 (enExample) |
| KR (1) | KR102057508B1 (enExample) |
| CN (1) | CN103857405B (enExample) |
| AU (1) | AU2012267470C1 (enExample) |
| BR (1) | BR112013031539A2 (enExample) |
| CA (1) | CA2837445C (enExample) |
| CY (1) | CY1118430T1 (enExample) |
| DK (1) | DK2717896T3 (enExample) |
| ES (1) | ES2607986T3 (enExample) |
| HR (1) | HRP20161566T1 (enExample) |
| HU (1) | HUE032087T2 (enExample) |
| LT (1) | LT2717896T (enExample) |
| MX (1) | MX337613B (enExample) |
| PL (1) | PL2717896T3 (enExample) |
| PT (1) | PT2717896T (enExample) |
| RS (1) | RS55503B1 (enExample) |
| RU (1) | RU2612912C2 (enExample) |
| SG (1) | SG195290A1 (enExample) |
| SI (1) | SI2717896T1 (enExample) |
| SM (2) | SMT201700081T1 (enExample) |
| WO (1) | WO2012170955A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201406921SA (en) | 2009-07-29 | 2014-11-27 | Kai Pharmaceuticals Inc | Therapeutic agents for reducing parathyroid hormone levels |
| CN105764487A (zh) | 2013-06-28 | 2016-07-13 | 美国安进公司 | Amg 416（velcalcetide）的稳定的液体制剂 |
| RU2686086C1 (ru) * | 2018-05-17 | 2019-04-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом |
| CN114222578B (zh) * | 2019-12-09 | 2024-06-25 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物及其应用 |
| EP4212542A4 (en) * | 2020-09-10 | 2024-08-28 | Shaanxi Micot Technology Co., Ltd. | BISPECIFIC FUSION POLYPEPTIDE COMPOUND |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| WO1992008476A1 (en) | 1990-11-07 | 1992-05-29 | The Scripps Research Institute | Peptides that inhibit platelet binding of adhesion molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| AU7634694A (en) | 1993-08-20 | 1995-03-21 | University Of Medicine And Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
| CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
| US5688489A (en) | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US5895368A (en) * | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
| US6165977A (en) | 1996-10-18 | 2000-12-26 | Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase C methods and compositions |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| JP2000336099A (ja) | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びｃ型肝炎抗体検出用試薬 |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| IL153378A0 (en) | 2000-07-18 | 2003-07-06 | Bone Care Internat Inc | STABILIZED 1alpha-HYDROXY VITAMIN D |
| US20080249016A1 (en) | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20020168354A1 (en) | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
| EP1351980B1 (en) | 2001-01-18 | 2014-12-31 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta pkc |
| US20030091640A1 (en) | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
| US20030036627A1 (en) | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
| ES2527339T3 (es) | 2001-02-23 | 2015-01-23 | Polyphor Ltd. | Peptidomiméticos fijados a patrón con actividad antimicrobiana |
| JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
| EP1576141A4 (en) | 2002-05-14 | 2006-03-22 | Bristol Myers Squibb Co | NEW HUMAN G-PROTEIN-COUPLED RECEPTORS CODING POLYNUCLEOTIDE AND SPLEISS VARIANTS THEREOF |
| WO2004093821A2 (en) | 2003-04-22 | 2004-11-04 | Hawaii Biotech, Inc. | Treatment of anthrax infection using inhibitors of lethal factor protease activity |
| WO2005049647A2 (en) | 2003-11-05 | 2005-06-02 | Pevion Biotech Ltd. | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
| WO2005059124A2 (en) | 2003-12-11 | 2005-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| US7939634B2 (en) | 2004-01-27 | 2011-05-10 | Compugen Ltd. | Polynucleotides encoding polypeptides and methods using same |
| US7265092B2 (en) | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| ITME20040015A1 (it) * | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| AU2006285127A1 (en) | 2005-08-30 | 2007-03-08 | Acologix, Inc. | Regulation of mineral and skeletal metabolism |
| WO2007038172A2 (en) | 2005-09-23 | 2007-04-05 | Nitto Denko Corporation | Guanidinium carriers |
| CN103961686A (zh) * | 2006-11-16 | 2014-08-06 | 凯制药公司 | 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽 |
| AU2008206077A1 (en) | 2007-01-19 | 2008-07-24 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
| JP5697450B2 (ja) | 2007-10-02 | 2015-04-08 | マリーナ バイオテック，インコーポレイテッド | 核酸の送達のためのリポペプチド |
| WO2009075773A2 (en) | 2007-12-07 | 2009-06-18 | Goldstein Steven A | Identification of toxin ligands |
| SG10201406921SA (en) * | 2009-07-29 | 2014-11-27 | Kai Pharmaceuticals Inc | Therapeutic agents for reducing parathyroid hormone levels |
-
2012
- 2012-06-08 WO PCT/US2012/041759 patent/WO2012170955A1/en not_active Ceased
- 2012-06-08 BR BR112013031539A patent/BR112013031539A2/pt not_active Application Discontinuation
- 2012-06-08 PT PT127289072T patent/PT2717896T/pt unknown
- 2012-06-08 SI SI201230784A patent/SI2717896T1/sl unknown
- 2012-06-08 HR HRP20161566TT patent/HRP20161566T1/hr unknown
- 2012-06-08 AU AU2012267470A patent/AU2012267470C1/en active Active
- 2012-06-08 DK DK12728907.2T patent/DK2717896T3/en active
- 2012-06-08 SM SM20170081T patent/SMT201700081T1/it unknown
- 2012-06-08 EP EP12728907.2A patent/EP2717896B1/en active Active
- 2012-06-08 PL PL12728907T patent/PL2717896T3/pl unknown
- 2012-06-08 CN CN201280038112.5A patent/CN103857405B/zh active Active
- 2012-06-08 SG SG2013089594A patent/SG195290A1/en unknown
- 2012-06-08 JP JP2014514910A patent/JP5982473B2/ja active Active
- 2012-06-08 ES ES12728907.2T patent/ES2607986T3/es active Active
- 2012-06-08 KR KR1020137034736A patent/KR102057508B1/ko active Active
- 2012-06-08 HU HUE12728907A patent/HUE032087T2/en unknown
- 2012-06-08 US US13/492,778 patent/US8969299B2/en active Active
- 2012-06-08 RS RS20161021A patent/RS55503B1/sr unknown
- 2012-06-08 LT LTEP12728907.2T patent/LT2717896T/lt unknown
- 2012-06-08 CA CA2837445A patent/CA2837445C/en active Active
- 2012-06-08 RU RU2013157928A patent/RU2612912C2/ru active IP Right Revival
- 2012-06-08 MX MX2013014249A patent/MX337613B/es active IP Right Grant
-
2016
- 2016-11-24 CY CY20161101220T patent/CY1118430T1/el unknown
-
2017
- 2017-02-06 SM SM201700081T patent/SMT201700081B/it unknown